Functional phenotyping of human plasma using a 361‐fluorogenic substrate biosensing microarray

A microarray presenting glycerol nanodroplets of fluorogenic peptide substrates was used as a biosensor for the detection of multiple enzyme activities within human plasma. Using 10 different plasma proteases (kallikrein, factor XIIa, factor XIa, factor IXa, factor VIIa, factor Xa, thrombin, activated protein C, uPA and plasmin) and a 361‐compound fluorogenic substrate library (Ac‐Ala‐P3‐P2‐Arg‐coumarin for P = all amino acids except Cys), a database was created for deconvoluting the relative activity of each individual enzyme signal in human plasma treated with various activators (calcium, kaolin, or uPA). Three separate deconvolution protocols were tested: searching for “optimal” sensing substrate sequences for a set of 5 enzymes and using these substrates to detect protease signals in plasma; ranking the “optimal” sensing substrates for 10 proteases using local error minimization, resulting in a set of substrates which were bundled via weighted averaging into a super‐pixel that had biosensing properties not obtainable by any individual fluorogenic substrate; and treating each 361‐element map measured for each plasma preparation as a weighted sum of the 10 maps obtained for the 10 purified enzymes using a global error minimization. The similarity of the results from these latter two protocols indicated that a small subset of <90 substrates contained the majority of biochemical information. The results were consistent with the state of the coagulation cascade expected when treated with the given activators. This method may allow development of future biosensors using minimal and non‐specific markers. These substrates can be applied to real‐time diagnostic biosensing of complex protease mixtures. © 2006 Wiley Periodicals, Inc.

[1]  S. Iwanaga,et al.  New Fluorogenic Substrates for α-Thrombin, Factor Xa, Kallikreins, and Urokinase , 1977 .

[2]  K. C. Jones,et al.  A Model for the Stoichiometric Regulation of Blood Coagulation* , 2002, The Journal of Biological Chemistry.

[3]  C. Lawson,et al.  Solving least squares problems , 1976, Classics in applied mathematics.

[4]  J. Oldenburg,et al.  Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. , 2001, Blood.

[5]  Scott L Diamond,et al.  Profiling serine protease substrate specificity with solution phase fluorogenic peptide microarrays , 2005, Proteomics.

[6]  Wylie Burke,et al.  Genomics as a probe for disease biology. , 2003, The New England journal of medicine.

[7]  G. Broze,et al.  Factor XI activation in a revised model of blood coagulation , 1991, Science.

[8]  Scott L Diamond,et al.  Printing chemical libraries on microarrays for fluid phase nanoliter reactions , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Abrahams,et al.  The Functional Integrity of the Serpin Domain of C1-inhibitor Depends on the Unique N-terminal Domain, as Revealed by a Pathological Mutant* , 2003, Journal of Biological Chemistry.

[10]  U. Okamoto,et al.  Production of the modified form of human plasminogen in the plasma activated by urokinase. , 1983, The Japanese journal of physiology.

[11]  C. Hack,et al.  Modulation of Contact System Proteases by Glycosaminoglycans , 1996, The Journal of Biological Chemistry.

[12]  L. Chao,et al.  Novel Roles of Kallistatin, a Specific Tissue Kallikrein Inhibitor, in Vascular Remodeling , 2001, Biological chemistry.

[13]  J. Griffin,et al.  Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Thomas Orfeo,et al.  The Significance of Circulating Factor IXa in Blood* , 2004, Journal of Biological Chemistry.

[15]  K. Mann,et al.  Tissue factor activity in whole blood. , 2005, Blood.

[16]  S. Diamond,et al.  High Throughput Substrate Specificity Profiling of Serine and Cysteine Proteases Using Solution-phase Fluorogenic Peptide Microarrays* , 2005, Molecular & Cellular Proteomics.

[17]  Y. Nemerson,et al.  Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein , 2003, Nature Medicine.

[18]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[19]  L. Seipel,et al.  The thrombolytic paradox. , 2001, Thrombosis research.

[20]  Francesco Leonetti,et al.  Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin , 2000, Nature Biotechnology.

[21]  T. Veenstra,et al.  The Human Plasma Proteome , 2004, Molecular & Cellular Proteomics.

[22]  Charles L. Lawson,et al.  Solving least squares problems , 1976, Classics in applied mathematics.

[23]  H. Kato,et al.  Clinical‐scale high‐throughput human plasma proteome analysis: Lung adenocarcinoma , 2005, Proteomics.

[24]  J. Griffin,et al.  The biochemistry and pathophysiology of the contact system of plasma. , 1982, Advances in immunology.

[25]  Kenneth G. Mann,et al.  Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II* , 1997, The Journal of Biological Chemistry.

[26]  E. Diamandis Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[27]  K. Mann,et al.  The dynamics of thrombin formation. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[28]  E. Petricoin,et al.  Toxicoproteomics: Serum Proteomic Pattern Diagnostics for Early Detection of Drug Induced Cardiac Toxicities and Cardioprotection , 2004, Toxicologic pathology.

[29]  G. Ewald,et al.  Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. , 1995, Circulation.

[30]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[31]  P. Schoen,et al.  The in situ inhibition of prothrombinase-formed human alpha-thrombin and meizothrombin(des F1) by antithrombin III and heparin. , 1987, The Journal of biological chemistry.

[32]  S. Iwanaga,et al.  New fluorogenic substrates for alpha-thrombin, factor Xa, kallikreins, and urokinase. , 1977, Journal of Biochemistry (Tokyo).

[33]  E. Davie,et al.  Waterfall Sequence for Intrinsic Blood Clotting , 1964, Science.

[34]  M. Mayer,et al.  Biochemical and biological aspects of the plasminogen activation system. , 1990, Clinical biochemistry.

[35]  D. Rijken,et al.  Basic principles in thrombolysis: regulatory role of plasminogen. , 2001, Thrombosis research.

[36]  Scott L Diamond,et al.  Blood coagulation kinetics: high throughput method for real-time reaction monitoring , 2004, Thrombosis and Haemostasis.

[37]  M. Ferrari,et al.  Clinical proteomics: Written in blood , 2003, Nature.